He Qi, Wang Jie, Shao Yu-guo, Zhou Xiao-yun, Shao Zhi-min
Department of Breast Disease, International Peace Maternity & Child Health Hospital, Shanghai Jiaotong University, Shanghai 200030, China.
Zhonghua Yi Xue Za Zhi. 2009 Feb 3;89(4):243-7.
To investigate the clinical-pathological characteristics of triple negative breast cancer.
The clinical-pathological characteristics of 690 breast cancer patients, all females, 127 being estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER)-2 triple negative, were analyzed.
The expression rate of P53, a tumor suppressor gene, of the triple negative breast cancer patients was 71.42% (75/127), significantly higher than that of the non-triple negative breast cancer patients (42.56%, P < 0.01), and the expression rate of epidermal growth factor receptor (EGFR) of the triple negative breast cancer was 59.74%, significantly higher than that of the non-triple negative breast cancer patients (22.06%, P = 0.013). The local lymph node metastasis rate of the triple negative breast cancer was 22.22%, significantly higher than that of the non-triple negative breast cancer patients (2.70%, P = 0.048). The 5-year overall survival (OS) rate and 10-year OS rate of he triple negative breast cancer patients were 79.67% and 63.15% respectively, both significantly lower than those of the non-triple negative breast cancer patients (88.59% and 83.28% respectively, both P = 0.001). The 5-year and 10-year disease free survival (DFS) rates of the triple negative breast cancer patients were 77.94% and 62.87% respectively, both significantly lower than those of the non-triple negative breast cancer patients (83.82% and 82.53% respectively, both P = 0.011), especially that within 36 months.
Triple negative breast cancer is related with P53 and EGFR expression, and tends to metastasize to local lympho-nodes. The survival rate of triple negative breast cancer patients is significantly lower than that of non-triple negative breast cancer.
探讨三阴性乳腺癌的临床病理特征。
分析690例女性乳腺癌患者的临床病理特征，其中127例为雌激素受体（ER）、孕激素受体（PR）及人表皮生长因子受体（HER）-2三阴性。
三阴性乳腺癌患者抑癌基因P53的表达率为71.42%（75/127），显著高于非三阴性乳腺癌患者（42.56%，P<0.01）；三阴性乳腺癌患者表皮生长因子受体（EGFR）的表达率为59.74%，显著高于非三阴性乳腺癌患者（22.06%，P=0.013）。三阴性乳腺癌局部淋巴结转移率为22.22%，显著高于非三阴性乳腺癌患者（2.70%，P=0.048）。三阴性乳腺癌患者5年总生存率（OS）和10年OS率分别为79.67%和63.15%，均显著低于非三阴性乳腺癌患者（分别为88.59%和83.28%，P均=0.001）。三阴性乳腺癌患者5年和10年无病生存率（DFS）分别为77.94%和62.87%，均显著低于非三阴性乳腺癌患者（分别为83.82%和82.53%，P均=0.011），尤其是36个月内。
三阴性乳腺癌与P53和EGFR表达有关，且易发生局部淋巴结转移。三阴性乳腺癌患者生存率显著低于非三阴性乳腺癌患者。
